Mutual fund · AMFI 118756
Nippon India Pharma Fund
NAV ₹179.63 · 17 Nov 2026
Nippon India Pharma Fund is a sectoral fund mutual fund run by . Its NAV was ₹179.63 on 17 Nov 2026, up 4.5% over one year and 9.2% a year over three years. The direct plan's total expense ratio was 0.98% in the latest AMFI data. The top 10 holdings made up 57.2% of the portfolio in October 2026.
Returns from NAV
One year and shorter are absolute; three and five years are annualised. Based on NAV, so dividend payouts are not added back. Past performance does not guarantee future results.
Risk · last 3.0 years
How bumpy the ride has been
Worked out from weekly NAVs. The largest fall ran from 02 Jan 2025 to 28 Feb 2025. Sharpe and Sortino use a fixed 6.5% a year risk-free rate for comparison. Past figures are not a guide to future returns.
What the fund charges
From AMFI's expense ratio data, updated 19 Nov 2026. The regular plan charges more; see the fund's factsheet.
Portfolio · October 2026
Top holdings (37 in total)
| Company | % of fund | vs last month |
|---|---|---|
| Sun Pharmaceutical Industries Limited | -0.16 | |
| Divi's Laboratories Limited | -0.37 | |
| Cipla Limited | +0.2 | |
| Lupin Limited | -0.01 | |
| Dr. Reddy's Laboratories Limited | +0.68 | |
| Apollo Hospitals Enterprise Limited | +0.21 | |
| Mankind Pharma Limited | +0.02 | |
| Sai Life Sciences Limited | +0.12 | |
| Ajanta Pharma Limited | -0.08 | |
| Max Healthcare Institute Limited | +0.61 | |
| IPCA Laboratories Limited | +0.03 | |
| GlaxoSmithKline Pharmaceuticals Limited | -0.28 | |
| Gland Pharma Limited | +0.2 | |
| Vijaya Diagnostic Centre Limited | +0.04 | |
| Piramal Pharma Limited | +0.37 |
The top 10 make up 57.2% of the fund. Source: the fund house's monthly portfolio disclosure.
Since September 2026
What changed
New holdings
- Natco Pharma Limited0.9%
Biggest changes in weight
- Fortis Healthcare Limited1.13% to 2.25%
By sector
Where the money is
Pharmaceuticals & Biotechnology75.0%
Healthcare Services21.8%
Retailing2.3%
Healthcare Equipment & Supplies0.5%
Learn more
Mutual fund guides
Your mutual funds
Review your own mutual fund portfolio
Upload or fetch your holdings and see each fund's returns, cost and overlap against benchmarks, as facts. Review my mutual funds
Questions
About Nippon India Pharma Fund
What is the NAV of Nippon India Pharma Fund?
The net asset value was Rs 179.63 on 17 November 2026.
What is the expense ratio of Nippon India Pharma Fund?
The direct plan's total expense ratio was 0.98% in the latest AMFI data, about Rs 9,800 a year on Rs 10 lakh invested.
What is the one-year return of Nippon India Pharma Fund?
The NAV changed by 4.5% over the last year; past returns do not indicate future returns.
Data: AMFI NAVs and expense ratios and the fund house's monthly portfolio disclosures. This page states facts and is not a recommendation to buy or sell. Mutual fund investments are subject to market risks; read all scheme-related documents carefully. Past performance does not guarantee future results.